Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2015 4
2016 2
2017 3
2018 4
2019 9
2020 5
2021 7
2022 5
2023 3
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Distler O, et al. Among authors: gahlemann m. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112379 Free article. Clinical Trial.
Nintedanib in children and adolescents with fibrosing interstitial lung diseases.
Deterding R, Young LR, DeBoer EM, Warburton D, Cunningham S, Schwerk N, Flaherty KR, Brown KK, Dumistracel M, Erhardt E, Bertulis J, Gahlemann M, Stowasser S, Griese M; InPedILD trial investigators. Deterding R, et al. Among authors: gahlemann m. Eur Respir J. 2023 Feb 2;61(2):2201512. doi: 10.1183/13993003.01512-2022. Print 2023 Feb. Eur Respir J. 2023. PMID: 36041751 Free PMC article. Clinical Trial.
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, Maher TM; SENSCIS trial investigators. Highland KB, et al. Among authors: gahlemann m. Lancet Respir Med. 2021 Jan;9(1):96-106. doi: 10.1016/S2213-2600(20)30330-1. Lancet Respir Med. 2021. PMID: 33412120 Free article. Clinical Trial.
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study.
Kole TM, Vanden Berghe E, Kraft M, Vonk JM, Nawijn MC, Siddiqui S, Sun K, Fabbri LM, Rabe KF, Chung KF, Nicolini G, Papi A, Brightling C, Singh D, van der Molen T, Dahlén SE, Agusti A, Faner R, Wedzicha JA, Donaldson GC, Adcock IM, Lahousse L, Kerstjens HAM, van den Berge M; ATLANTIS; U-BIOPRED; CADSET investigators. Kole TM, et al. Lancet Respir Med. 2023 Jan;11(1):55-64. doi: 10.1016/S2213-2600(22)00185-0. Epub 2022 Jul 27. Lancet Respir Med. 2023. PMID: 35907424
Exhaled Volatile Organic Compounds for Asthma Control Classification in Children with Moderate to Severe Asthma: Results from the SysPharmPediA Study.
Shahbazi Khamas S, Van Dijk Y, Abdel-Aziz MI, Neerincx AH, Maarten Blankestijn J, Vijverberg SJH, Hashimoto S, Bush A, Kraneveld AD, Hedman AM, Toncheva AA, Almqvist C, Wolff C, Murray CS, Hedlin G, Roberts G, Adcock IM, Korta-Murua J, Bønnelykke K, Fleming LJ, Pino-Yanes M, Gorenjak M, Kabesch M, Sardón-Prado O, Montuschi P, Singer F, Elosegui PC, Fowler SJ, Brandstetter S, Harner S, Dahlén SE, Potočnik U, Frey U, van Aalderen W, Brinkman P, Maitland-van der Zee AH; SysPharmPediA and U-BIOPRED Consortia. Shahbazi Khamas S, et al. Am J Respir Crit Care Med. 2024 Nov 1;210(9):1091-1100. doi: 10.1164/rccm.202312-2270OC. Am J Respir Crit Care Med. 2024. PMID: 38648186
Exploring geographic differences in IgE response through network and manifold analyses.
Cucco A, Pearce N, Simpson A, Pembrey L, Mpairwe H, Figueiredo CA, Cooper PJ, Douwes J, Brooks C, Adcock IM, Kermani NZ, Roberts GDM, Murray CS, Custovic A, Fontanella S; WASP Study Group; STELAR/UNICORN Consortium; U-BIOPRED Consortium. Cucco A, et al. J Allergy Clin Immunol. 2025 Jun 30:S0091-6749(25)00702-X. doi: 10.1016/j.jaci.2025.05.032. Online ahead of print. J Allergy Clin Immunol. 2025. PMID: 40602688 Free article.
Treatable traits in the European U-BIOPRED adult asthma cohorts.
Simpson AJ, Hekking PP, Shaw DE, Fleming LJ, Roberts G, Riley JH, Bates S, Sousa AR, Bansal AT, Pandis I, Sun K, Bakke PS, Caruso M, Dahlén B, Dahlén SE, Horvath I, Krug N, Montuschi P, Sandstrom T, Singer F, Adcock IM, Wagers SS, Djukanovic R, Chung KF, Sterk PJ, Fowler SJ; U-BIOPRED Study Group. Simpson AJ, et al. Allergy. 2019 Feb;74(2):406-411. doi: 10.1111/all.13629. Epub 2018 Nov 12. Allergy. 2019. PMID: 30307629 Free PMC article. No abstract available.
Stratification of asthma phenotypes by airway proteomic signatures.
Schofield JPR, Burg D, Nicholas B, Strazzeri F, Brandsma J, Staykova D, Folisi C, Bansal AT, Xian Y, Guo Y, Rowe A, Corfield J, Wilson S, Ward J, Lutter R, Shaw DE, Bakke PS, Caruso M, Dahlen SE, Fowler SJ, Horváth I, Howarth P, Krug N, Montuschi P, Sanak M, Sandström T, Sun K, Pandis I, Riley J, Auffray C, De Meulder B, Lefaudeux D, Sousa AR, Adcock IM, Chung KF, Sterk PJ, Skipp PJ, Djukanović R; U-BIOPRED Study Group. Schofield JPR, et al. J Allergy Clin Immunol. 2019 Jul;144(1):70-82. doi: 10.1016/j.jaci.2019.03.013. Epub 2019 Mar 28. J Allergy Clin Immunol. 2019. PMID: 30928653 Free article.
39 results